Antitumor activity of a ROR1 × CD3 bispecific antibody in non-small cell lung cancer
International Immunopharmacology · 2023
DOI: 10.1016/j.intimp.2023.110686 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Immunopharmacology, 2023. Verfasst von Yi Wang und 14 weiteren Autor:innen. Beteiligte Einrichtung: School of Basic Medical Sciences, Chengdu University of Traditional Chinese Medicine, Chengdu 611137, China. Hauptthemen laut MEDLINE: Antibodies, Bispecific, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 42 Literaturangaben.
Abstract (Originalsprache)
Over the last decade, immuno-oncologic drugs especially CD3-engaging bispecific antibodies (biAbs) are experiencing fast-paced evolution, but big challenges still exist in the clinical development of biAbs in solid tumors, especially non-small cell lung cancer (NSCLC). In this study, we choose a ROR1 × CD3 biAb in scFv-Fc format, named R11 × v9 biAb, to investigate its tumor-inhibiting role in NSCLC. Notably, the ROR1-engaging arm binds both human and mouse ROR1. We found that R11 × v9 biAb specifically binds T cells and tumor cells simultaneously, and dose-dependent cytotoxicity was detected for various ROR1+ NSCLC cell lines. Further, R11 × v9 biAb mediated T-cell derived proinflammatory cytokine secretion, boosted granzyme B and perforin production from CD8+ T cells, and recruited more CD4+ T cells and CD8+ T cells into the tumor tissues. The antitumor activity of R11 × v9 biAb was confirmed in two xenograft mouse models of ROR1+ NSCLC. Importantly, no harmful side effects were observed in these in vivo studies, warranting further preclinical and clinical studies of R11 × v9 biAb in NSCLC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Basic Medical Sciences, Chengdu University of Traditional Chinese Medicine, Chengdu 611137, China.
- Department of Pathology, the First People's Hospital of Yunnan Province, Kunming 650034, China.
- School of Medical and Life Sciences, Chengdu University of Traditional Chinese Medicine, Chengdu 611137, China.
- School of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu 611137, China.
- The Affiliated Wuxi People's Hospital of Nanjing Medical University, Wuxi People's Hospital, Wuxi Medical Center, Nanjing Medical University, Wuxi 214023, China. Electronic address: wuwenjung@163.com.
- School of Basic Medical Sciences, Chengdu University of Traditional Chinese Medicine, Chengdu 611137, China. Electronic address: zhoushiyi@cdutcm.edu.cn.
Zitieren
APA
Wang, Y., Zhang, Y., Sun, H., Chen, J., Yang, H., Zhong, Z., Xiao, X., Li, Y., Tang, Y., Lu, H., Tang, X., Zhang, M., Wu, W., Zhou, S., & Yang, J. (2023). Antitumor activity of a ROR1 × CD3 bispecific antibody in non-small cell lung cancer. International Immunopharmacology. https://doi.org/10.1016/j.intimp.2023.110686
Vancouver
Wang Y, Zhang Y, Sun H, Chen J, Yang H, Zhong Z, et al. Antitumor activity of a ROR1 × CD3 bispecific antibody in non-small cell lung cancer. International Immunopharmacology. 2023. doi:10.1016/j.intimp.2023.110686
BibTeX
@article{Wang2023,
author = {Wang, Yi and Zhang, Yuxi and Sun, Haoyi and Chen, Jilan and Yang, Hui and Zhong, Zhanqiong and Xiao, Xiaoqian and Li, Yanping and Tang, Yibei and Lu, Haolan and Tang, Xinzhi and Zhang, Mengyang and Wu, Wenjun and Zhou, Shiyi and Yang, Jiahui},
title = {Antitumor activity of a ROR1 × CD3 bispecific antibody in non-small cell lung cancer},
journal = {International Immunopharmacology},
year = {2023},
doi = {10.1016/j.intimp.2023.110686}
}
EUVIMED